-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下：我们将ALGN的12个月目标股价从193美元下调至189美元。这一新目标股价相当于我们2026年每股收益预期值的16.7倍，高于ALGN过去一年的平均预期市盈率15.7倍，但远低于其过去三年和五年的平均市盈率24.3倍和31.4倍。我们将2026年每股收益预期上调0.06美元至11.34美元，并将2027年每股收益预期上调0.15美元至12.36美元。尽管我们预计利率将继续下降，但我们认为在当前的宏观经济环境下，北美地区的患者数量仍然面临挑战，通胀压力抑制了消费者信心和选择性医疗支出。第一季度平均每箱出货价格上涨约 1% 至 1,250 美元，环比和同比上涨 10 美元，但 ALGN 预计 2026 年价格将下降 1%-2%。
Related Articles
Australia
Argus Cuts Price Target on Thermo Fisher Scientific to $560 From $610
Thermo Fisher Scientific (TMO) has an average rating of buy and mean price target of $623.91, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $478.09, Change: $+11.83, Percent Change: +2.54%
$TMO
Australia
JPMorgan Adjusts Price Target on Royal Caribbean Group to $345 From $341, Maintains Overweight Rating
Royal Caribbean Group (RCL) has an average rating of overweight and mean price target of $345.35, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $266.70, Change: $+12.69, Percent Change: +5.00%
$RCL
Australia
HSBC Cuts Microsoft Price Target to $571 From $593
Microsoft (MSFT) has an average rating of Buy and mean price target of $562.51, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $403.97, Change: $-20.50, Percent Change: -4.83%
$MSFT